ECSP21012501A - Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas - Google Patents
Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadasInfo
- Publication number
- ECSP21012501A ECSP21012501A ECSENADI202112501A ECDI202112501A ECSP21012501A EC SP21012501 A ECSP21012501 A EC SP21012501A EC SENADI202112501 A ECSENADI202112501 A EC SENADI202112501A EC DI202112501 A ECDI202112501 A EC DI202112501A EC SP21012501 A ECSP21012501 A EC SP21012501A
- Authority
- EC
- Ecuador
- Prior art keywords
- nash
- treatment
- nafld
- combinations
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe en la presente la combinación de (S)-2-(5-((3-etoxi-piridin-2-il)oxi)piridin-3-il)-N-(tetrahidrofuran-3-il)pirimidina-5-carboxamida, o una sal farmacéuticamente aceptable de la misma, y ácido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro-[indazol-5,4-piperidina]-1-carbonil)-6-metoxipiridin-2-il)benzoico, o sal farmacéuticamente aceptable del mismo, para tratamiento de enfermedades, incluyendo esteatohepatitis no alcohólica (EHNA), en mamíferos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862726172P | 2018-08-31 | 2018-08-31 | |
US201962883860P | 2019-08-07 | 2019-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21012501A true ECSP21012501A (es) | 2021-03-31 |
Family
ID=68165623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202112501A ECSP21012501A (es) | 2018-08-31 | 2021-02-23 | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
Country Status (22)
Country | Link |
---|---|
US (2) | US11254660B2 (es) |
EP (1) | EP3843740A1 (es) |
JP (1) | JP7161605B2 (es) |
KR (1) | KR102614808B1 (es) |
CN (1) | CN112955147A (es) |
AU (1) | AU2019329884B2 (es) |
BR (1) | BR112021003039A2 (es) |
CA (1) | CA3110601C (es) |
CL (1) | CL2021000491A1 (es) |
CO (1) | CO2021002230A2 (es) |
CR (1) | CR20210110A (es) |
DO (1) | DOP2021000036A (es) |
EC (1) | ECSP21012501A (es) |
IL (1) | IL281093A (es) |
MA (1) | MA53496A (es) |
MX (1) | MX2021002428A (es) |
PH (1) | PH12021550339A1 (es) |
SG (1) | SG11202101503RA (es) |
TW (1) | TWI718644B (es) |
UY (1) | UY38351A (es) |
WO (1) | WO2020044266A1 (es) |
ZA (1) | ZA202101090B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11590161B2 (en) * | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
CR20210341A (es) * | 2018-11-22 | 2021-11-25 | Qilu Regor Therapeutics Inc | Agonistas de glp-ir y usos de los mismos |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Nafld/nashおよび関連疾患の処置のための組合せ |
JP2022058085A (ja) * | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ |
EP4098261A4 (en) * | 2020-03-11 | 2024-02-28 | Dong A St Co Ltd | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS |
WO2021211959A2 (en) * | 2020-04-18 | 2021-10-21 | Inipharm, Inc. | Methods and compositions for treating drug induced steatohepatitis |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN113816948B (zh) * | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
US20220089578A1 (en) * | 2020-08-21 | 2022-03-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
CN112635049A (zh) * | 2020-12-23 | 2021-04-09 | 无锡市第二人民医院 | 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法 |
WO2023169456A1 (en) | 2022-03-09 | 2023-09-14 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
CZ200172A3 (cs) | 1998-07-06 | 2001-08-15 | Bristol-Myers Squibb Company | Bifenylsulfonamidy jako duální antagonisty receptoru angiotensinového a endothelinového receptoru |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
EE05440B1 (et) | 2001-02-28 | 2011-08-15 | Merck & Co., Inc. | Atslitud piperidiini derivaadid kui melanokortiin-4 retseptori agonistid, farmatseutiline kompositsioon ning kasutamine ravimi valmistamiseks |
NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
SI1753748T1 (sl) | 2004-05-12 | 2009-12-31 | Pfizer Prod Inc | Derivati prolina in njihova uporaba kot inhibitorji dipeptidil-peptidaze IV |
UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
ATE552262T1 (de) | 2006-11-29 | 2012-04-15 | Pfizer Prod Inc | Spiroketone als inhibitoren von acetyl-coa- carboxylase |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
JP2011521940A (ja) | 2008-05-28 | 2011-07-28 | ファイザー・インク | ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
GEP20135803B (en) | 2008-08-28 | 2013-04-10 | Pfizer | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
CN102388038B (zh) | 2009-03-11 | 2014-04-23 | 辉瑞大药厂 | 用作葡糖激酶活化剂的苯并呋喃基衍生物 |
EP2408780A2 (en) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloý3.3.1¨nonanes |
EP2427450A1 (en) | 2009-05-08 | 2012-03-14 | Pfizer Inc. | Gpr 119 modulators |
CA2759891A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
JP2012528847A (ja) | 2009-06-05 | 2012-11-15 | ファイザー・インク | Gpr119調節因子としてのl−(ピペリジン−4−イル)−ピラゾール誘導体 |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
RS55224B1 (sr) | 2010-09-30 | 2017-02-28 | Pfizer | N1-pirazolospiroketon acetil-coa karboksilaza inhibitori |
CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
WO2016112305A1 (en) | 2015-01-09 | 2016-07-14 | Nimbus Apollo, Inc. | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
GEP20207147B (en) | 2015-12-29 | 2020-09-10 | Pfizer | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
AR109179A1 (es) * | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
BR112019012211A2 (pt) | 2016-12-16 | 2019-11-12 | Pfizer | agonistas de receptor de glp-1 e usos dos mesmos |
SG11202003600QA (en) | 2017-11-21 | 2020-06-29 | Pfizer | Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid |
-
2019
- 2019-08-28 CA CA3110601A patent/CA3110601C/en active Active
- 2019-08-28 SG SG11202101503RA patent/SG11202101503RA/en unknown
- 2019-08-28 WO PCT/IB2019/057259 patent/WO2020044266A1/en active Application Filing
- 2019-08-28 CR CR20210110A patent/CR20210110A/es unknown
- 2019-08-28 CN CN201980071389.XA patent/CN112955147A/zh active Pending
- 2019-08-28 EP EP19783644.8A patent/EP3843740A1/en active Pending
- 2019-08-28 JP JP2021510174A patent/JP7161605B2/ja active Active
- 2019-08-28 BR BR112021003039-5A patent/BR112021003039A2/pt unknown
- 2019-08-28 TW TW108130771A patent/TWI718644B/zh active
- 2019-08-28 AU AU2019329884A patent/AU2019329884B2/en active Active
- 2019-08-28 KR KR1020217009415A patent/KR102614808B1/ko active IP Right Grant
- 2019-08-28 MX MX2021002428A patent/MX2021002428A/es unknown
- 2019-08-28 US US16/553,818 patent/US11254660B2/en active Active
- 2019-08-28 MA MA053496A patent/MA53496A/fr unknown
- 2019-08-29 UY UY0001038351A patent/UY38351A/es unknown
-
2021
- 2021-02-17 ZA ZA2021/01090A patent/ZA202101090B/en unknown
- 2021-02-17 PH PH12021550339A patent/PH12021550339A1/en unknown
- 2021-02-23 EC ECSENADI202112501A patent/ECSP21012501A/es unknown
- 2021-02-23 CO CONC2021/0002230A patent/CO2021002230A2/es unknown
- 2021-02-24 IL IL281093A patent/IL281093A/en unknown
- 2021-02-25 DO DO2021000036A patent/DOP2021000036A/es unknown
- 2021-02-26 CL CL2021000491A patent/CL2021000491A1/es unknown
- 2021-10-11 US US17/498,256 patent/US20220023299A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202026292A (zh) | 2020-07-16 |
IL281093A (en) | 2021-04-29 |
WO2020044266A1 (en) | 2020-03-05 |
MX2021002428A (es) | 2023-01-02 |
UY38351A (es) | 2020-03-31 |
US20200071306A1 (en) | 2020-03-05 |
PH12021550339A1 (en) | 2021-10-04 |
CN112955147A (zh) | 2021-06-11 |
CA3110601C (en) | 2023-09-05 |
CA3110601A1 (en) | 2020-03-05 |
ZA202101090B (en) | 2022-06-29 |
TWI718644B (zh) | 2021-02-11 |
KR20210053929A (ko) | 2021-05-12 |
KR102614808B1 (ko) | 2023-12-19 |
CO2021002230A2 (es) | 2021-03-08 |
BR112021003039A2 (pt) | 2021-05-18 |
CR20210110A (es) | 2021-05-13 |
MA53496A (fr) | 2021-12-08 |
JP2021535126A (ja) | 2021-12-16 |
AU2019329884B2 (en) | 2022-01-27 |
CL2021000491A1 (es) | 2021-08-20 |
EP3843740A1 (en) | 2021-07-07 |
US11254660B2 (en) | 2022-02-22 |
US20220023299A1 (en) | 2022-01-27 |
SG11202101503RA (en) | 2021-03-30 |
DOP2021000036A (es) | 2021-04-15 |
AU2019329884A1 (en) | 2021-03-11 |
JP7161605B2 (ja) | 2022-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21012501A (es) | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas | |
ECSP20013248A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
BR112013029246A2 (pt) | 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
RU2017105353A (ru) | Соединения | |
AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
UY29964A1 (es) | Formas de cristal f,g,h,i, y k del mesilato de imatinib | |
BR112015030578A2 (pt) | combinações farmacêuticas | |
MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. | |
JO3789B1 (ar) | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة | |
BRPI0921692A2 (pt) | composto carbamato ou o sal do mesmo | |
PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
RU2019111873A (ru) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм | |
AR065477A1 (es) | Diaminopirimidinas | |
CO6260065A2 (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
CL2021000160A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
UY38345A (es) | Composición farmacéutica que comprende agente antiplaquetario e inhibidor de la secreción de ácido g |